Trial Profile

A Phase 3, Multi-centric, Single blind, Randomized, Comparative study to assess the efficacy and safety of fixed dose combination of Telmisartan + Amlodipine + Hydrochlorothiazide bi-layered tablet verses Telmisartan + Hydrochlorothiazide tablet for the treatment in patients with essential hypertension.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amlodipine/telmisartan/hydrochlorothiazide (Primary) ; Telmisartan/hydrochlorothiazide
Indications Essential hypertension
Focus Therapeutic Use
Sponsors Aristo Pharmaceuticals

10 Jun 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
05 Jun 2010 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com